You are here

The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Tosei General Hospital
Seto-shi, Aichi-ken, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16-79 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 16 years of age or older.

- Patients who were diagnosed as moderate to severe community acquired pneumonia
requiring initial intravenous therapy and hospitalization.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam
sodium, other penicillins, or cephems.

- Hepatic dysfunction [Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT),
total bilirubin > 3 times upper limit of normal range values].

- Severe renal dysfunction (creatinine clearance

- Severe underlying disease; patients in which drug clinical evaluation is difficult
because of confounding diseases.

NCT01189487
Pfizer
Completed
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now